James Gordon
Stock Analyst at JP Morgan
(2.80)
# 1,711
Out of 5,113 analysts
11
Total ratings
75%
Success rate
22.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Gordon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $925 → $1,100 | $854.99 | +28.66% | 8 | Dec 8, 2025 | |
| GRFS Grifols | Maintains: Neutral | $7.6 → $10 | $9.02 | +14.19% | 1 | Jun 17, 2025 | |
| GMAB Genmab | Downgrades: Neutral | n/a | $32.38 | - | 1 | Aug 20, 2024 | |
| FGEN FibroGen | Upgrades: Neutral | n/a | $8.60 | - | 1 | Apr 7, 2021 |
argenx SE
Dec 8, 2025
Maintains: Overweight
Price Target: $925 → $1,100
Current: $854.99
Upside: +28.66%
Grifols
Jun 17, 2025
Maintains: Neutral
Price Target: $7.6 → $10
Current: $9.02
Upside: +14.19%
Genmab
Aug 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $32.38
Upside: -
FibroGen
Apr 7, 2021
Upgrades: Neutral
Price Target: n/a
Current: $8.60
Upside: -